ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases

Open Access

Publisher Website

15 July 2003

journal article
case report
Published by Springer Nature in British Journal of Cancer

Vol. 89 (2) , 246-247
https://doi.org/10.1038/sj.bjc.6601116

Abstract

No abstract available

Keywords

This publication has 4 references indexed in Scilit:

Evaluation of response: new and standard criteria
Annals of Oncology, 2002
Pleural mesothelioma: combined modality treatments
Annals of Oncology, 2002
Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD1839 (IressaTM), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR)
Lung Cancer, 2000
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
2000